Living channels.
Programmable flow.
A self-assembling microfluidic platform built from engineered Neurospora crassa, with septal pore valves addressed by light instead of pneumatics. No cleanroom in the critical path.
Microfluidics is stuck in the cleanroom.
Every experiment starts with a photomask and weeks of fabrication. Biology moved on — microfluidics hasn't.
2–4 weeks per chip, $5k–$20k per mask
PDMS fabrication requires a cleanroom. Each design change means a new photomask — slow iteration, high cost, high barrier to entry.
Passive channels — no programmability
Active valves require complex external pneumatic systems. No built-in actuation. No design reusability across projects.
Single-use waste — clogging kills the chip
Channel fouling is terminal. Each clog means discarding the device and restarting fabrication from scratch.
Market Opportunity
$25B
Microfluidics market by 2028 — growth limited by fabrication bottlenecks and passive chip designs.
The Core Bottleneck
Every experiment starts with a cleanroom. Biology moved on — microfluidics hasn't.
One fungus. One week. Zero cleanroom.
Sivoro replaces photolithography with engineered fungi that self-assemble into precision microfluidic channels.
| Feature | Sivoro Living Chip | Conventional PDMS |
|---|---|---|
| Fabrication | Fungus grows channels | Photolithography (cleanroom) |
| Valves | Light-addressed, 450 nm, intrinsic | Pneumatic, external control lines |
| Valve density | Set by projection optics | Set by control-line routing |
| Iteration | Days (transform strain) | Weeks (redesign mask) |
| Channel recovery | Hyphal turnover (target behavior) | Terminal (chip disposal) |
Five patent families, three technical layers
From metabolic chassis to optogenetic valve to physical scaffold, all covered by US provisional application 64/087,071.
Layer 1 — Chassis
Metabolically Orthogonal N. crassa
Engineered to run on xylose while uptake of reagent sugars and metabolites is substantially reduced — roughly 87% of reagent uptake blocked. Six-gene knockout selected in silico from 10,440 combinations screened.
Layer 2 — Valve
Optogenetic Septal Pore Valve
Blue light (450 nm) drives recruitment at the septal pore. LOV2-Jα-HEX1 fusion protein + SPA1-ePDZ pore-rim anchor. Designed and modeled; dark/lit contrast is what Gate 2 measures.
Layer 3 — Scaffold
H-Tree Scaffold & Integration
Parametric design (10×10 mm, 16 ports). Compatible with SU-8/PDMS or direct printing. Channel dimensions engineered for 2–8 hyphae (13–20 µm width, 15 µm depth).
Computational phases complete.
Two experimental gates next.
Metabolic modeling, the knockout screen, valve design, and scaffold design are done. Two biophysical measurements now determine whether the valve works: HEX1 oligomerization by SEC-MALS, and light-dependent binding by BLI.
Chassis construction follows those results rather than preceding them.
View the validation sequence →-
Metabolic modeling, KO screen, valve design, scaffold design
Complete — all computational
-
SEC-MALS on CompA_v3
Gate — does HEX1 oligomerize in the fusion? Mw ≥ 1000 kDa
-
BLI — Jα motif to ePDZ anchor
Gate — does it bind under light? ≥10× dark/lit contrast
-
Six-gene chassis construction
-
Valve function in hypha
-
Prototype chip colonization
-
First academic beta site
The only living, self-assembling microfluidic platform
Sivoro occupies a unique position: simple fabrication, active biological control. No competitor is in this quadrant.
| Competitor | Sivoro Advantage |
|---|---|
| Emulate, Inc. | No living channels; $200k+ instruments |
| CN Bio Innovations | Lower cost, faster iteration |
| Micronit | No cleanroom required |
| Fluidigm / Standard BioTools | 10× lower price; biological actuation |
X axis: Active control · Y axis: Fabrication simplicity
Computational validation complete
10,440
Knockout pairs screened in silico
16
Strains clearing the chip-integration threshold
2
Optogenetic constructs designed, codon-optimized, and structurally modeled
7,600+
Lines of modeling and analysis code
145
Gene candidate pool behind the screen
64/087,071
US provisional application, filed June 10, 2026
IP Status
US provisional application 64/087,071, filed June 10, 2026 · 5 claim families · sole applicant, no institutional encumbrance
$1.5M
18 months runway to a functional prototype
- Round
- Seed
- Pre-money
- $6M
- Post-money
- $7.5M
- Runway
- 18 mo
The round starts with two measurements, SEC-MALS and BLI, that decide whether the valve works, then carries the work through chassis construction to a prototype chip. Series A follows in Q4 2027.